Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551249 · ClinicalTrials.gov registry record · NA
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
A NA study of Glioblastoma and Glioma, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT03551249: Completed NA study of Glioblastoma and Glioma, sponsored by InSightec.
NCT03551249 is a NA study of Glioblastoma and Glioma that has completed, run by InSightec. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03551249, a NA study of Glioblastoma and Glioma, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
Primary Outcome
The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE
Conditions Studied
Interventions
- DEVICE Focused ultrasound (FUS)
Study Locations (4)
Maryland
- University of Maryland - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Virginia
- University of Virginia - Charlottesville
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
What the finished NCT03551249 record still lists
NCT03551249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Focused ultrasound (FUS) is the first listed.
NCT03551249 reports a single indexed study location in Maryland, Massachusetts, Virginia.
Frequently Asked Questions
What is clinical trial NCT03551249 about?
NCT03551249 is a clinical study titled "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption". The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
What is the current status of trial NCT03551249?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2019-03-26. Estimated completion is 2023-12-31.
What conditions does trial NCT03551249 study?
This clinical trial studies the following conditions: Glioblastoma, Glioma.
What interventions are being tested in trial NCT03551249?
The interventions under investigation include: Focused ultrasound (FUS) (DEVICE).
Who is sponsoring clinical trial NCT03551249?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03551249 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, Virginia, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03551249's enrollment target sits among peer trials
20 148th of 199 higher than 46 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI